Screening for Cervical Cancer - Systematic Evidence Review (Number 25)

By:

U.S. Department of Health and Human Services

Format:

Paperback / softback

Show Hide Adult Content

$64.99

Available from supplier

Usually ships in 3-4 weeks

0 in Trolley

Price Match

Wrap this item as a gift ($5.90) - add a free gift card on the next page

Buy Now, Pay Later with:

Afterpay is available on orders $100 to $2000 Learn more

Availability

Delivering to:

Estimated arrival:

Around 3-13 June using International Courier

Description

The evidence we reviewed indicates that a reasonable age at which to initiate cervical cancer screening in women is age 21. Screening before this age is complicated by relatively high rates of transient HPV and regressive cervical abnormalities, with very few actual cancer cases. Current data cannot assure that beginning screening after this age is clearly safe, particularly in the United States, which has no centralized national cervical cancer screening program. For cytology-based screening, LBC does not differ from CC in sensitivity, specificity, or relative CIN detection, but may yield a lower proportion of unsatisfactory slides. Cost, overall screening strategy, and other considerations may also pertain to local decisions on which approach to use for collecting cytology samples. In women older than age 30 years, a single HC2 test is clearly more sensitive for CIN2+ and CIN3+ (about 40% greater) than cytology alone. However, a single HC2 test is also 3 to 5 percent less specific than cytology.

Release date Australia

October 31st, 2015

Author

U.S. Department of Health and Human Services

Audience

General (US: Trade)

Pages

166

Dimensions

216x280x9

ISBN-13

9781329660335

Product ID

24580270

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here